Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of akkermansia for treating metabolic disorders

a metabolic disorder and akkermansia technology, applied in the field of metabolic disorders, can solve the problems of imbalance in the metabolism of carbohydrates, lipids, proteins and/or nucleic acids, and the beneficial effect of direct administration of akkermansia muciniphila has never been described, nor suggested, and achieves the effect of increasing the energy expenditure of said subjects, increasing the energy expenditure of subjects, and increasing the energy expenditur

Inactive Publication Date: 2019-09-19
UNIVERSITE CATHOLIQUE DE LOUVAIN +1
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0031]“Probiotics” refers to microbial cell preparations (such as, for example, living microbial cells) or components of microbial cells which, when administered in an effective amount, provide a beneficial effect on the health or well-being of a subject. By definition, all probiotics have a proven non-pathogenic character. In one embodiment, these health benefits are associated with improving the balance of human or animal microbiota in the gastro-intestinal tract, and / or restoring normal microbiota.
[0122]In one embodiment, the administration of Akkermansia muciniphila or a fragment thereof to a subject increases satiety in said subject. Consequently, according to this embodiment, the method of the invention increases satiety in a subject, thereby inducing durable weight loss in the subject, and thereby treating metabolic disorders in said subject, such as, for example, obesity related metabolic disorders.

Problems solved by technology

However, this may be an indirect effect due to the insensitivity of intestinal Akkermansia spp. to the used antibiotic.
Moreover, to the Applicant knowledge, no beneficial effect of the direct administration of Akkermansia muciniphila has never been described, nor suggested.
A metabolic disorder may be associated with either a deficiency or an excess in a metabolic pathway resulting in an imbalance in metabolism of carbohydrates, lipids, proteins and / or nucleic acids.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of akkermansia for treating metabolic disorders
  • Use of akkermansia for treating metabolic disorders
  • Use of akkermansia for treating metabolic disorders

Examples

Experimental program
Comparison scheme
Effect test

examples

[0135]The present invention is further illustrated by the following examples.

[0136]Materials and Methods

[0137]Mice

[0138]Ob / Ob Experiment:

[0139]ob / ob versus lean study: Six-week-old ob / ob (n=5 / group) mice (C57BL / 6 background, Jackson-Laboratory, Bar Harbor, Me., USA) were housed in a controlled environment (12-h daylight cycle, lights-off at 6-pm) in groups of two or three mice / cage, with free access to food and water. The mice were fed a control diet (A04, Villemoisson-sur-Orge, France) for 16 weeks. Cecal content was harvested immersed in liquid nitrogen, and stored at −80° C., for further Akkermansia muciniphila analysis.

[0140]Ob / Ob Prebiotic Study:

[0141]Six-week-old ob / ob (n=10 / group) mice (C57BL / 6 background, Jackson-Laboratory, Bar Harbor, Me., USA) were housed in a controlled environment (12-h daylight cycle, lights-off at 6-pm) in groups of two mice / cage, with free access to food and water. The mice were fed a control diet (Ob-CT) (A04, Villemoisson-sur-Orge, France) or a con...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to Akkermansia muciniphila or fragments thereof for treating a metabolic disorder in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition and a medicament comprising Akkermansia muciniphila or fragments thereof for treating a metabolic disorder. The present invention also relates to the use of Akkermansia muciniphila or fragments thereof for promoting weight loss in a subject in need thereof.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a divisional application of U.S. application Ser. No. 14 / 443,829, filed May 19, 2015, currently pending; which is a 371 of International Application PCT / EP2013 / 073972, filed Nov. 15, 2013; which claims priority to PCT / EP2012 / 073011, filed Nov. 19, 2012. The contents of all above-named applications are incorporated herein by reference.REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY[0002]The content of the electronically submitted sequence listing in ASCII text file (Name: 4139_0020002_Seqlisting_ST25.txt; Size: 6,231 bytes; and Date of Creation: Feb. 25, 2019) is incorporated herein by reference in its entirety.FIELD OF INVENTION[0003]The present invention relates to the treatment of metabolic disorders, such as, for example, metabolic disorders related to overweight and obesity, such as, for example, Diabetes Mellitus or high cholesterol. The present invention more specifically relates to a composition comprisin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K35/74A61K9/00A61K35/741A23L2/38
CPCA61K9/0053A61K35/74A61K35/741Y02A50/481A61P3/00A61P1/16A61P11/00A61P11/06A61P19/02A61P25/00A61P25/28A61P3/04A61P35/00A61P3/06A61P37/02A61P37/04A61P43/00A61P9/00A61P9/10A61P9/12A61P3/10Y02A50/30A23L33/135A23V2002/00A23V2200/308
Inventor CANI, PATRICEEVERARD, AMANDINEBELZER, CLARADE VOS, WILLEM
Owner UNIVERSITE CATHOLIQUE DE LOUVAIN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com